Capturing value: IP as a driver for investment

Door Peter Wilson,

Patents, trademarks, designs and other forms of intellectual property (IP) play a key role in the success of all modern businesses. By providing a company with a legal means to prevent others from copying an invention, brand or product, IP rights enable inventors and creators to obtain a return on their investments in research and development, and to maximise the potential of their businesses, as Dr Peter Wilson explains.

Whether directly or indirectly, consciously or unconsciously, IP will play a major role in any company’s future success. A company’s brand value or its product or innovation portfolio are key value differentiators, providing plenty of strategic reasons for initial and ongoing investment. In order to capture that value, however, investors need to be sure that their target companies keep on top of their IP assets, including protecting intangible assets and keeping the associated rights and records up-to-date and in force.

IP attorneys can – and should – be brought in to support investors during the assessment and due diligence phases of a potential investment. Typically, this will include:

  • IP auditing to assess the validity and extent of a target business’s existing and potential IP rights.
  • Due diligence to ensure the correct chain of ownership is in place and to identify the existence of potential third-party objections or claims.
  • Patent landscaping to review IP rights in relation to their technology space, and thereby identify a patent’s strength or vulnerability in light of market activity.
  • Freedom-to-operate studies to identify conflicting rights in order to assess how vulnerable the business may be to an infringement suit or litigation.
  • IP consultancy to identify strategies for strengthening rights and shoring up portfolios based on vulnerabilities identified during the above analyses.

Getting IP ready for investment

Before investors even get to the due diligence phase, however, most will begin by reviewing potential investment opportunities from an IP perspective. Therefore, companies looking to attract venture capitalists, private equity firms or even industry grants or loans would also be wise to focus on capturing and shoring up their IP assets before they even begin the process of looking for funding or external investment.

Depending on the company, this will typically include asking internal stakeholders:

  • Have patent rights been put in place for all core inventions, including defensive filings where relevant?
  • Has the company or product’s brand and/or visual appearance been protected as trademark/design rights in all key jurisdictions?
  • Is the IP’s ownership clear and up-to-date; for example, where it has been created by multiple stakeholders or passed from one company to another?
  • How crowded is the market and technology space for any new/core inventions – is there a risk of a third-party infringement claim?
  • Where does the IP sit in relation to competitor activity – does the portfolio need to be reinforced with additional filings?
  • Does additional IP exist in the business that has yet to be protected?
  • How do the identified strengths and weaknesses of its IP portfolio impact on a business’s value and potential?

In an ideal world, IP will have been diligently captured, maintained and recorded as a company grows and expands; unfortunately, this is not always the case. By overlooking their core assets, however, companies risk short-changing themselves when it comes to attracting investment and maximising their future chances of business success.

It’s also important to remember that not all IP exists as registered rights and so an assessment of all company documents will generally be needed to locate other valuable intangible assets, such as copyright or confidential information, licences or distribution rights.

Dr Peter Wilson is a Patent Attorney at Novagraaf in Norwich, UK

Laatste inzichten

Hot topics

Rebranding van generieke geneesmiddelen door parallelimporteurs: wanneer is dat toegestaan ?

Het recht om een geneesmiddel uit het ene EU-land te exporteren en in een ander EU-land in te voeren zonder uitdrukkelijke toestemming van de merkhouder is toegestaan op grond van  het EU-beginsel van het vrije verkeer van goederen. De regel geldt voor zowel generieke als originele merkgeneesmiddelen mits aan de specifieke nationale en EU-voorwaarden voor parallelimport van geneesmiddelen wordt voldaan. 

Door Novagraaf Team,
Rebranding van generieke geneesmiddelen door parallelimporteurs: wanneer is dat toegestaan ?
Nieuws en opinie

Registratie van een niet-conventioneel merk of vormmerk: een somber vooruitzicht voor de Louboutins van de toekomst?

Niet-conventionele merken zijn merken die een vorm, kleur, geur of geluid beschermen. Ondanks dat ze maar een klein deel uitmaken van alle merken in het register, zijn ze een populair en innovatief middel voor bedrijven om hun producten of diensten te onderscheiden.

Door Novagraaf Team,
Registratie van een niet-conventioneel merk of vormmerk: een somber vooruitzicht voor de Louboutins van de toekomst?
Nieuws en opinie

Aftellen naar INTA 2023: brand protection gaat niet alleen over merken

De jaarlijkse bijeenkomst van de International Trademark Association (INTA) vindt dit jaar plaats in Singapore (16-20 mei) en belooft een boeiende conferentie te worden. De sessies die voor  de conferentie zijn gepland, benadrukken dat merkenrechten niet de enige rechten zijn waarmee rekening moet worden gehouden als het gaat om brand protection.

Door Luke Portnow,
Aftellen naar INTA 2023: brand protection gaat niet alleen over merken

Voor meer informatie neem gerust contact met ons op.

Cookie policy

Om de bezoekers van de website de best mogelijke ervaring te bieden, maakt Novagraaf gebruik van cookies. Door op "Accepteren" te klikken of door de site verder te gebruiken, gaat u akkoord met ons privacybeleid, inclusief ons cookiebeleid.